BUSINESS

Fycompa Designated for Priority Review in China

January 9, 2019
Chinese regulators have granted a priority review status to Eisai’s anti-epilepsy drug perampanel, otherwise known as Fycompa, as an adjunctive treatment for partial onset seizures in epilepsy patients 12 years of age and older. The Japanese drug maker said on…

To read the full story

BUSINESS

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…